Enoximone
From Infogalactic: the planetary knowledge core
| File:Enoximone.svg | |
| Systematic (IUPAC) name | |
|---|---|
|
4-methyl-5-{[4-(methylsulfanyl)phenyl]carbonyl}-2,3-dihydro-1H-imidazol-2-one
|
|
| Clinical data | |
| AHFS/Drugs.com | International Drug Names |
| Legal status |
|
| Routes of administration |
Intravenous |
| Pharmacokinetic data | |
| Bioavailability | 50% (oral) |
| Protein binding | 85% |
| Metabolism | Hepatic oxidation |
| Biological half-life | 4 to 10 hours |
| Excretion | Renal (60 to 70%) |
| Identifiers | |
| CAS Number | 77671-31-9  |
| ATC code | C01CE03 (WHO) |
| PubChem | CID: 53708 |
| DrugBank | DB04880 |
| ChemSpider | 48492 |
| UNII | C7Z4ITI7L7 |
| KEGG | D04004 |
| ChEMBL | CHEMBL249856 |
| Chemical data | |
| Formula | C12H12N2O2S |
| Molecular mass | 248.302 g/mol |
|
|
|
|
| (verify) | |
Enoximone (INN, trade name Perfan) is an imidazole phosphodiesterase inhibitor. It is used in the treatment of congestive heart failure and is selective for phosphodiesterase 3.[1]
References
<templatestyles src="Reflist/styles.css" />
Cite error: Invalid <references> tag; parameter "group" is allowed only.
<references />, or <references group="..." /><templatestyles src="Asbox/styles.css"></templatestyles>
 |
This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
